Pivotal bioVenture Partners Investment Advisor LLC
CIK 1844645 · View on SEC EDGAR ↗
- Portfolio value
- $307.8M
- Positions
- 13
- As of
- June 30, 2026
Portfolio value QoQ: +10.0% 13F does not disclose cash
- Top 10 holdings weight
- 95.12%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 12
- Effective number of positions
- 7.7
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 2.56% Est. buys $40,986,230 · sells $7,530,759
Median holding: 4.0 quarters Tracked Q4 2024–Q2 2026 · 68.4% still held
- New positions
- 1
- Increased
- 3
- Decreased
- 4
- Closed
- 1
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Annualized: +22.8% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 96.4% · Options excluded: 0.0%
Sector breakdown
Full portfolio 13 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte, Inc. - Common Stock | $82,862,571 | 26.92% | 1,425,470 | $3,110,954 | Up ×1 | ||
| ARQT Arcutis Biotherapeutics, Inc. - Common stock | $33,175,720 | 10.78% | 1,265,283 | $1,230,904 | Down ×3 | ||
| TRVI Trevi Therapeutics, Inc. - Common Stock | $32,500,833 | 10.56% | 1,742,672 | $13,964,882 | Up ×2 | ||
| Unknown issuer (CUSIP: 05348Y105) | $31,826,793 | 10.34% | 966,792 | Up ×1 | |||
| EVMN Evommune, Inc. Common Stock | $25,609,072 | 8.32% | 1,926,943 | $-18,691,348 | |||
| MPLT MapLight Therapeutics, Inc. - Common Stock | $21,914,225 | 7.12% | 611,446 | $9,483,507 | Down ×1 | ||
| OCS Oculis Holding AG - Ordinary shares | $20,891,688 | 6.79% | 1,506,250 | $-23,787,037 | Down ×3 | ||
| BIOA BioAge Labs, Inc. - Common Stock | $16,014,197 | 5.20% | 653,374 | $4,586,686 | |||
| IMNM Immunome, Inc. - Common Stock | $15,521,929 | 5.04% | 732,512 | $-498,108 | |||
| ZBIO Zenas BioPharma, Inc. - Common Stock | $12,455,641 | 4.05% | 490,766 | $882,217 | Down ×1 | ||
| AVTX Avalo Therapeutics, Inc. - Common Stock | $8,020,930 | 2.61% | 434,033 | $3,602,650 | Up ×1 | ||
| RLYB Rallybio Corporation - Common Stock | $4,809,264 | 1.56% | 300,579 | $2,113,070 | |||
| RXRX Recursion Pharmaceuticals, Inc. - Class A Common Stock | $2,185,551 | 0.71% | 595,518 | $357,311 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| Unknown issuer (CUSIP: 05348Y105) | $31,826,793 | 966,792 | 10.34% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| OCS | Trimmed | -174K | -$23.8M |
| EVMN | Price move only | +0 | -$18.7M |
| TRVI | Bought more | +189K | +$14.0M |
| MPLT | Trimmed | -1 | +$9.5M |
| BIOA | Price move only | +0 | +$4.6M |
| AVTX | Bought more | +138K | +$3.6M |
| PCVX | Bought more | +53K | +$3.1M |
| RLYB | Price move only | +0 | +$2.1M |
| ARQT | Trimmed | -91K | +$1.2M |
| ZBIO | Trimmed | -101K | +$882K |
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| INZY | Sept. 30, 2025 | 4,494,851 | $17,979,404 | No longer tracked |
| VIGL | Sept. 30, 2025 | 560,595 | $4,456,730 | No longer tracked |
| IOBT | Sept. 30, 2025 | 864,197 | $1,201,234 | No longer tracked |
| BOLT | June 30, 2026 | 42,581 | $172,027 | -13.8% |